MLL_NN
and_CC
CALM_NN
are_VBP
fused_VBN
to_TO
AF10_NN
in_IN
morphologically_RB
distinct_JJ
subsets_NNS
of_IN
acute_JJ
leukemia_NN
with_IN
translocation_NN
t_NN
-LRB-_-LRB-
10_CD
;_:
11_CD
-RRB-_-RRB-
:_:
both_DT
rearrangements_NNS
are_VBP
associated_VBN
with_IN
a_DT
poor_JJ
prognosis_NN
._.

The_DT
translocation_NN
t_NN
-LRB-_-LRB-
10_CD
;_:
11_CD
-RRB-_-RRB-
-LRB-_-LRB-
p13_NN
;_:
q14_NN
-RRB-_-RRB-
has_VBZ
been_VBN
observed_VBN
in_IN
acute_JJ
lymphoblastic_JJ
leukemia_NN
-LRB-_-LRB-
ALL_NN
-RRB-_-RRB-
as_RB
well_RB
as_IN
acute_JJ
myeloid_JJ
leukemia_NN
-LRB-_-LRB-
AML_NN
-RRB-_-RRB-
._.

A_DT
recent_JJ
study_NN
showed_VBD
a_DT
MLL\/AF10_NN
fusion_NN
in_IN
all_DT
cases_NNS
of_IN
AML_NN
with_IN
t_NN
-LRB-_-LRB-
10_CD
;_:
11_CD
-RRB-_-RRB-
and_CC
various_JJ
breakpoints_NNS
on_IN
chromosome_NN
11_CD
ranging_VBG
from_IN
q13_NN
to_TO
q23_NN
._.

We_PRP
recently_RB
cloned_VBD
CALM_NN
-LRB-_-LRB-
Clathrin_NN
Assembly_NN
Lymphoid_JJ
Myeloid_JJ
leukemia_NN
gene_NN
-RRB-_-RRB-
,_,
the_DT
fusion_NN
partner_NN
of_IN
AF10_NN
at_IN
11q14_NN
in_IN
the_DT
monocytic_JJ
cell_NN
line_NN
U937_NN
._.

To_TO
further_RB
define_VB
the_DT
role_NN
of_IN
these_DT
genes_NNS
in_IN
acute_JJ
leukemias_NNS
,_,
10_CD
cases_NNS
-LRB-_-LRB-
9_CD
AML_NN
and_CC
1_CD
ALL_NN
-RRB-_-RRB-
with_IN
cytogenetically_RB
proven_JJ
t_NN
-LRB-_-LRB-
10_CD
;_:
11_CD
-RRB-_-RRB-
-LRB-_-LRB-
p12-14_NN
;_:
q13-21_NN
-RRB-_-RRB-
and_CC
well-characterized_VBD
morphology_NN
,_,
immunophenotype_NN
,_,
and_CC
clinical_JJ
course_NN
were_VBD
analyzed_VBN
._.

Interphase_NN
fluorescence_NN
in_FW
situ_FW
hybridization_NN
-LRB-_-LRB-
FISH_NN
-RRB-_-RRB-
was_VBD
performed_VBN
with_IN
2_CD
YACs_NNS
flanking_VBG
the_DT
CALM_NN
region_NN
,_,
a_DT
YAC_NN
contig_NN
of_IN
the_DT
MLL_NN
region_NN
,_,
and_CC
a_DT
YAC_NN
spanning_VBG
the_DT
AF10_NN
breakpoint_NN
._.

Rearrangement_NN
of_IN
at_IN
least_JJS
one_CD
of_IN
these_DT
genes_NNS
was_VBD
detected_VBN
in_IN
all_DT
cases_NNS
with_IN
balanced_JJ
t_NN
-LRB-_-LRB-
10_CD
;_:
11_CD
-RRB-_-RRB-
._.

In_IN
4_CD
cases_NNS
,_,
including_VBG
3_CD
AML_NN
with_IN
immature_JJ
morphology_NN
-LRB-_-LRB-
1_CD
AML-M0_NN
and_CC
2_CD
AML-M1_NN
-RRB-_-RRB-
and_CC
1_CD
ALL_NN
,_,
the_DT
signals_NNS
of_IN
the_DT
CALM_NN
YACS_NNS
were_VBD
separated_VBN
in_IN
interphase_JJ
cells_NNS
,_,
indicating_VBG
a_DT
translocation_NN
breakpoint_NN
within_IN
the_DT
CALM_NN
region_NN
._.

MLL_NN
was_VBD
rearranged_VBN
in_IN
3_CD
AML_NN
with_IN
myelomonocytic_JJ
differentiation_NN
-LRB-_-LRB-
2_CD
AML-M2_NN
and_CC
1_CD
AML-M5_NN
-RRB-_-RRB-
,_,
including_VBG
1_CD
secondary_JJ
AML_NN
._.

In_IN
all_DT
3_CD
cases_NNS
,_,
a_DT
characteristic_JJ
immunophenotype_NN
was_VBD
identified_VBN
-LRB-_-LRB-
CD4_NN
+_NN
,_,
CD13_NN
-_:
,_,
CD33_NN
+_NN
,_,
CD65s_NNP
+_NNP
-RRB-_-RRB-
._.

AF-10_NN
was_VBD
involved_VBN
in_IN
5_CD
of_IN
6_CD
evaluable_JJ
cases_NNS
,_,
including_VBG
1_CD
case_NN
without_IN
detectable_JJ
CALM_NN
or_CC
MLL_NN
rearrangement_NN
._.

In_IN
2_CD
complex_NN
translocations_NNS
,_,
none_NN
of_IN
the_DT
three_CD
genes_NNS
was_VBD
rearranged_VBN
._.

All_DT
cases_NNS
had_VBD
a_DT
remarkably_RB
poor_JJ
prognosis_NN
,_,
with_IN
a_DT
mean_JJ
survival_NN
of_IN
9.6_NN
+_CC
\/_NN
-_:
6.6_JJ
months_NNS
._.

For_IN
the_DT
7_CD
AML_NN
cases_NNS
that_WDT
were_VBD
uniformly_RB
treated_VBN
according_VBG
to_TO
the_DT
AMLCG86\/92_NN
protocols_NNS
,_,
disease-free_JJ
and_CC
overall_JJ
survival_NN
was_VBD
significantly_RB
worse_JJ
than_IN
for_IN
the_DT
overall_JJ
study_NN
group_NN
-LRB-_-LRB-
P_NN
=_JJ
.03_CD
and_CC
P_NN
=_JJ
.01_CD
,_,
respectively_RB
-RRB-_-RRB-
._.

We_PRP
conclude_VBP
that_IN
the_DT
t_NN
-LRB-_-LRB-
10_CD
;_:
11_CD
-RRB-_-RRB-
-LRB-_-LRB-
p13_NN
;_:
q14_NN
-RRB-_-RRB-
indicates_VBZ
CALM_NN
and_CC
MLL_NN
rearrangements_NNS
in_IN
morphologically_RB
distinct_JJ
subsets_NNS
of_IN
acute_JJ
leukemia_NN
and_CC
may_MD
be_VB
associated_VBN
with_IN
a_DT
poor_JJ
prognosis_NN
._.

